Fig. 1: Kaplan–Meier curve for progression-free survival.
From: Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas
Kaplan–Meier estimates of PFS are shown. There were 22 PFS events among 25 patients. The median PFS was 7.6 months (90% CI: 3.4–12.9).
